Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$22.81
+1.7%
$23.24
$14.10
$26.01
$2.84B0.5672,187 shs154,967 shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.33
-2.6%
$3.86
$1.25
$14.55
$355.03M1.839.79 million shs5.35 million shs
10x Genomics, Inc. stock logo
TXG
10x Genomics
$26.49
-3.7%
$38.54
$26.30
$63.57
$3.16B1.91.47 million shs504,067 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
+1.04%+0.63%-8.19%-10.64%+7.06%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-7.48%-2.86%-62.33%-80.85%-86.68%
10x Genomics, Inc. stock logo
TXG
10x Genomics
-0.22%-5.62%-24.21%-35.09%-46.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
0.5402 of 5 stars
2.02.00.00.03.30.00.6
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.7264 of 5 stars
4.31.00.00.02.01.71.3
10x Genomics, Inc. stock logo
TXG
10x Genomics
4.2791 of 5 stars
3.42.00.04.82.53.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
2.00
Hold$26.0013.99% Upside
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.53
Moderate Buy$7.77486.62% Upside
10x Genomics, Inc. stock logo
TXG
10x Genomics
2.89
Moderate Buy$60.22127.34% Upside

Current Analyst Ratings

Latest TXG, OLK, and PACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
4/18/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$9.00 ➝ $2.50
4/18/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$7.00 ➝ $2.50
4/18/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $8.00
4/18/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $55.00
4/17/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $2.50
4/10/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $3.00
4/10/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$9.00 ➝ $7.00
4/10/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $45.00
3/26/2024
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$26.00
3/26/2024
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$26.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$169.60M16.72N/AN/A$4.04 per share5.65
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$200.52M1.77N/AN/A$2.62 per share0.51
10x Genomics, Inc. stock logo
TXG
10x Genomics
$618.73M5.10N/AN/A$6.22 per share4.26

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
-$31.60M-$0.25N/A570.25N/A-18.63%-6.50%-5.63%5/9/2024 (Estimated)
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$306.73M-$1.21N/AN/AN/A-152.97%-40.23%-15.24%5/9/2024 (Confirmed)
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$255.10M-$2.17N/AN/AN/A-41.17%-28.82%-22.67%4/30/2024 (Confirmed)

Latest TXG, OLK, and PACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.26N/A+$0.26N/AN/AN/A  
4/30/2024N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.46N/A+$0.46N/AN/AN/A  
3/25/2024Q4 2023
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$0.14-$0.06-$0.20-$0.06$82.80 million$68.55 million
2/15/202412/31/2023
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.29-$0.27+$0.02-$0.23$57.96 million$58.36 million    
2/15/2024Q4 2023
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.36-$0.41-$0.05-$0.41$182.73 million$183.98 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
N/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
N/A
4.75
3.55
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.27
7.81
7.21
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/A
4.69
4.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
30.19%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
5.20%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.90%
10x Genomics, Inc. stock logo
TXG
10x Genomics
10.65%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
707124.34 million117.88 millionOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
796267.95 million262.86 millionOptionable
10x Genomics, Inc. stock logo
TXG
10x Genomics
1,259119.17 million106.48 millionOptionable

TXG, OLK, and PACB Headlines

SourceHeadline
10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of "Moderate Buy" by Brokerages10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of "Moderate Buy" by Brokerages
americanbankingnews.com - April 25 at 1:38 AM
Down -23.92% in 4 Weeks, Heres Why 10x Genomics (TXG) Looks Ripe for a TurnaroundDown -23.92% in 4 Weeks, Here's Why 10x Genomics (TXG) Looks Ripe for a Turnaround
zacks.com - April 24 at 10:36 AM
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
zacks.com - April 23 at 11:06 AM
10x Genomics (TXG) Set to Announce Earnings on Tuesday10x Genomics (TXG) Set to Announce Earnings on Tuesday
americanbankingnews.com - April 23 at 4:54 AM
10x Genomics (TXG) to Release Earnings on Tuesday10x Genomics (TXG) to Release Earnings on Tuesday
marketbeat.com - April 23 at 4:47 AM
10x Genomics (TXG) Upgraded to Buy: Heres What You Should Know10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
zacks.com - April 22 at 1:01 PM
First Week of TXG June 21st Options TradingFirst Week of TXG June 21st Options Trading
nasdaq.com - April 21 at 3:32 AM
10x Genomics (NASDAQ:TXG) PT Lowered to $55.0010x Genomics (NASDAQ:TXG) PT Lowered to $55.00
americanbankingnews.com - April 20 at 4:32 AM
10x Genomics (NASDAQ:TXG) Shares Gap Down  on Analyst Downgrade10x Genomics (NASDAQ:TXG) Shares Gap Down on Analyst Downgrade
americanbankingnews.com - April 19 at 1:14 AM
Bruker to acquire Nanostring for $393MBruker to acquire Nanostring for $393M
medtechdive.com - April 18 at 3:02 PM
10x Genomics (NASDAQ:TXG) Shares Gap Down  Following Analyst Downgrade10x Genomics (NASDAQ:TXG) Shares Gap Down Following Analyst Downgrade
marketbeat.com - April 18 at 10:35 AM
10x Genomics, Inc. (TXG)10x Genomics, Inc. (TXG)
finance.yahoo.com - April 17 at 12:34 PM
10x Genomics (NASDAQ:TXG) Trading Down 5.9%10x Genomics (NASDAQ:TXG) Trading Down 5.9%
marketbeat.com - April 16 at 1:41 PM
10x Genomics, Inc. (NASDAQ:TXG) Shares Bought by Sumitomo Mitsui Trust Holdings Inc.10x Genomics, Inc. (NASDAQ:TXG) Shares Bought by Sumitomo Mitsui Trust Holdings Inc.
marketbeat.com - April 16 at 7:22 AM
SVB Wealth LLC Has $80.95 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)SVB Wealth LLC Has $80.95 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - April 15 at 10:06 PM
10x Genomics (NASDAQ:TXG) Hits New 52-Week Low at $33.4710x Genomics (NASDAQ:TXG) Hits New 52-Week Low at $33.47
marketbeat.com - April 15 at 2:48 PM
Cathie Woods ARK focuses on Teladoc and 10X Genomics stockCathie Wood's ARK focuses on Teladoc and 10X Genomics stock
investing.com - April 11 at 7:21 PM
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 202410x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
finance.yahoo.com - April 10 at 7:03 PM
10x Genomics (NASDAQ:TXG) Price Target Cut to $45.0010x Genomics (NASDAQ:TXG) Price Target Cut to $45.00
marketbeat.com - April 10 at 4:19 PM
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 202410x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
prnewswire.com - April 10 at 4:05 PM
10x Genomics (NASDAQ:TXG) Shares Gap Down to $37.3710x Genomics (NASDAQ:TXG) Shares Gap Down to $37.37
marketbeat.com - April 10 at 11:50 AM
Baillie Gifford & Co. Decreases Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)Baillie Gifford & Co. Decreases Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - April 9 at 12:12 PM
As 10x Launches Visium HD, Will Single Cell Resolution Draw New Customers?As 10x Launches Visium HD, Will Single Cell Resolution Draw New Customers?
genengnews.com - March 29 at 5:58 PM
ARK Investment Management LLC Acquires 1,047,827 Shares of 10x Genomics, Inc. (NASDAQ:TXG)ARK Investment Management LLC Acquires 1,047,827 Shares of 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - March 28 at 6:39 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Olink Holding AB (publ) logo

Olink Holding AB (publ)

NASDAQ:OLK
Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and data analysis and bioinformatics services. In addition, the company offers Olink normalized protein expression (NPX) data processing software, a purpose-built software that enable users to import data, perform data analysis including visualizations, and statistical modelling; and Olink Insight, a cloud platform for Olink community to accelerate proteomics. It sells its products and services through its own direct sales force in Sweden, the United States, rest of the Americas, rest of Europe, the Middle East, Africa, Japan, and internationally. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. Olink Holding AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
Pacific Biosciences of California logo

Pacific Biosciences of California

NASDAQ:PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
10x Genomics logo

10x Genomics

NASDAQ:TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.